HDM-SARS2-Spike-delta21 Citations (12)
Originally described in: Protocol and Reagents for Pseudotyping Lentiviral Particles with SARS-CoV-2 Spike Protein for Neutralization Assays.Crawford KHD, Eguia R, Dingens AS, Loes AN, Malone KD, Wolf CR, Chu HY, Tortorici MA, Veesler D, Murphy M, Pettie D, King NP, Balazs AB, Bloom JD Viruses. 2020 May 6;12(5). pii: v12050513. doi: 10.3390/v12050513. PubMed Journal
Articles Citing HDM-SARS2-Spike-delta21
| Articles |
|---|
| Dynamics of Neutralizing Antibody Titers in the Months After Severe Acute Respiratory Syndrome Coronavirus 2 Infection. Crawford KHD, Dingens AS, Eguia R, Wolf CR, Wilcox N, Logue JK, Shuey K, Casto AM, Fiala B, Wrenn S, Pettie D, King NP, Greninger AL, Chu HY, Bloom JD. J Infect Dis. 2021 Feb 3;223(2):197-205. doi: 10.1093/infdis/jiaa618. PubMed |
| Structure-guided T cell vaccine design for SARS-CoV-2 variants and sarbecoviruses. Nathan A, Rossin EJ, Kaseke C, Park RJ, Khatri A, Koundakjian D, Urbach JM, Singh NK, Bashirova A, Tano-Menka R, Senjobe F, Waring MT, Piechocka-Trocha A, Garcia-Beltran WF, Iafrate AJ, Naranbhai V, Carrington M, Walker BD, Gaiha GD. Cell. 2021 Aug 19;184(17):4401-4413.e10. doi: 10.1016/j.cell.2021.06.029. Epub 2021 Jun 30. PubMed |
| The ApoA-I mimetic peptide 4F attenuates in vitro replication of SARS-CoV-2, associated apoptosis, oxidative stress and inflammation in epithelial cells. Kelesidis T, Madhav S, Petcherski A, Cristelle H, O'Connor E, Hultgren NW, Ritou E, Williams DS, Shirihai OS, Reddy ST. Virulence. 2021 Dec;12(1):2214-2227. doi: 10.1080/21505594.2021.1964329. PubMed |
| Single-cell profiling of proteins and chromatin accessibility using PHAGE-ATAC. Fiskin E, Lareau CA, Ludwig LS, Eraslan G, Liu F, Ring AM, Xavier RJ, Regev A. Nat Biotechnol. 2022 Mar;40(3):374-381. doi: 10.1038/s41587-021-01065-5. Epub 2021 Oct 21. PubMed |
| The OM-85 bacterial lysate inhibits SARS-CoV-2 infection of epithelial cells by downregulating SARS-CoV-2 receptor expression. Pivniouk V, Pivniouk O, DeVries A, Uhrlaub JL, Michael A, Pivniouk D, VanLinden SR, Conway MY, Hahn S, Malone SP, Ezeh P, Churko JM, Anderson D, Kraft M, Nikolich-Zugich J, Vercelli D. J Allergy Clin Immunol. 2022 Mar;149(3):923-933.e6. doi: 10.1016/j.jaci.2021.11.019. Epub 2021 Dec 10. PubMed |
| Nanobody-Functionalized Cellulose for Capturing SARS-CoV-2. Sun X, Yang S, Al-Dossary AA, Broitman S, Ni Y, Guan M, Yang M, Li J. Appl Environ Microbiol. 2022 Mar 8;88(5):e0230321. doi: 10.1128/aem.02303-21. Epub 2022 Jan 5. PubMed |
| Dynamics of infection-elicited SARS-CoV-2 antibodies in children over time. Gentles LE, Kehoe L, Crawford KHD, Lacombe K, Dickerson J, Wolf C, Yuan J, Schuler S, Watson JT, Nyanseor S, Briggs-Hagen M, Saydah S, Midgley CM, Pringle K, Chu H, Bloom JD, Englund JA. medRxiv. 2022 Jan 25. doi: 10.1101/2022.01.14.22269235. PubMed |
| SARS-CoV-2 pan-variant inhibitory peptides deter S1-ACE2 interaction and neutralize delta and omicron pseudoviruses. Shah M, Ung Moon S, Hyun Kim J, Thanh Thao T, Goo Woo H. Comput Struct Biotechnol J. 2022;20:2042-2056. doi: 10.1016/j.csbj.2022.04.030. Epub 2022 Apr 26. PubMed |
| Immune recall improves antibody durability and breadth to SARS-CoV-2 variants. Chen Y, Tong P, Whiteman N, Moghaddam AS, Zarghami M, Zuiani A, Habibi S, Gautam A, Keerti F, Bi C, Xiao T, Cai Y, Chen B, Neuberg D, Wesemann DR. Sci Immunol. 2022 May 12:eabp8328. doi: 10.1126/sciimmunol.abp8328. PubMed |
| Converting non-neutralizing SARS-CoV-2 antibodies into broad-spectrum inhibitors. Weidenbacher PA, Waltari E, de Los Rios Kobara I, Bell BN, Morris MK, Cheng YC, Hanson C, Pak JE, Kim PS. Nat Chem Biol. 2022 Nov;18(11):1270-1276. doi: 10.1038/s41589-022-01140-1. Epub 2022 Sep 8. PubMed |
| A ferritin-based COVID-19 nanoparticle vaccine that elicits robust, durable, broad-spectrum neutralizing antisera in non-human primates. Weidenbacher PA, Sanyal M, Friedland N, Tang S, Arunachalam PS, Hu M, Kumru OS, Morris MK, Fontenot J, Shirreff L, Do J, Cheng YC, Vasudevan G, Feinberg MB, Villinger FJ, Hanson C, Joshi SB, Volkin DB, Pulendran B, Kim PS. Nat Commun. 2023 Apr 17;14(1):2149. doi: 10.1038/s41467-023-37417-9. PubMed |
| Decreased efficacy of a COVID-19 vaccine due to mutations present in early SARS-CoV-2 variants of concern. Weidenbacher PA, Friedland N, Sanyal M, Morris MK, Do J, Hanson C, Kim PS. bioRxiv. 2023 Jun 29:2023.06.27.546764. doi: 10.1101/2023.06.27.546764. Preprint. PubMed |
If you have published an article using this material, please email us at [email protected] to have your article added to this page.